CAREDX INC (CDNA)
US14167L1035 - Common Stock
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
Oversold Conditions For CareDx (CDNA)
CareDx Appoints Bryan Riggsbee to Its Board of Directors
Thursday Sector Laggards: Medical Instruments & Supplies, Diagnostics
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference
CDNA Makes Bullish Cross Above Critical Moving Average
CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.
CareDX pares loss, gains after jury awards $96M to Natera in patent dispute
CareDX (CDNA) stock dropped 5% in premarket trading after a jury awarded $96.3 million to Natera (NTRA) in a patent dispute, causing a total 22% decline.
First Week of CDNA March 15th Options Trading
CareDX stock slide continues after jury awards $96.3M to Natera in patent dispute
CareDX (CDNA) stock dropped 5% in premarket trading after a jury awarded $96.3 million to Natera (NTRA) in a patent dispute, causing a total 22% decline.
CareDx Issues Statement in Patent Infringement Case
CareDX drops after jury votes in favor of Natera in patent fight (NASDAQ:CDNA)
CareDX (CDNA) shares drop 7.2% as Natera (NTRA) wins patent lawsuit, marking the first phase of the jury verdict.
Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle
The company must pay $57 million in damages, but that's far less than expected.
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023
CareDx stock climbs after Q3 beats, guidance boost (NASDAQ:CDNA)
CareDx shares soar 26% as the medical equipment firm beats Q3 expectations and raises revenue outlook for 2023, citing strong balance sheet and goal for...
CareDx Non-GAAP EPS of -$0.18 beats by $0.22, revenue of $67.2M beats by $14.05M (NASDAQ:CDNA)
CareDx reports Q3 2023 results, beating expectations with non-GAAP EPS of -$0.18 and revenue of $67.2M.
CareDx Reports Third Quarter 2023 Results
CareDx to Report Third Quarter 2023 Financial Results
CareDx Announces CEO Transition
CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting
CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents
Commit To Buy CareDx At $5, Earn 15.5% Annualized Using Options
Oversold Conditions For CareDx (CDNA)
CareDx To Present at the 2023 Cantor Global Healthcare Conference
